NCT04648865

A Study of LY3537031 in Healthy Participants

A Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3537031 in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 20 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3537031 in healthy participants. The blood tests will be performed to check how much LY3537031 gets into the bloodstream, how long the body takes to eliminate it and how body handles LY3537031. Each participant will receive a single dose of LY3537031 or placebo. The study will last up to approximately 71 days for each participant, including screening.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY3537031	Administered SC.
DRUG	Placebo	Administered SC.

Timeline

• Start date: 2020-12-09
• Primary completion: 2021-06-04
• Completion: 2021-06-04
• First posted: 2020-12-02
• Last updated: 2021-06-21

Locations

1 site across 1 country: Japan